Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · IEX Real-Time Price · USD
1.640
+0.070 (4.46%)
At close: Jul 19, 2024, 4:00 PM
1.670
+0.030 (1.83%)
Pre-market: Jul 22, 2024, 6:04 AM EDT
Coherus BioSciences Stock Forecast
CHRS's stock price has decreased by -62.56% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Coherus BioSciences stock have an average target of 8.50, with a low estimate of 7.00 and a high estimate of 12. The average target predicts an increase of 418.29% from the current stock price of 1.64.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CHRS stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $9 → $8 | Buy | Maintains | $9 → $8 | +387.80% | Jul 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +631.71% | May 24, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $8 → $7 | Strong Buy | Maintains | $8 → $7 | +326.83% | May 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $12 | Strong Buy | Maintains | $11 → $12 | +631.71% | May 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $13 → $11 | Strong Buy | Maintains | $13 → $11 | +570.73% | Mar 20, 2024 |
Financial Forecast
Revenue This Year
266.81M
from 257.24M
Increased by 3.72%
Revenue Next Year
342.23M
from 266.81M
Increased by 28.27%
EPS This Year
-1.37
from -2.53
EPS Next Year
-0.18
from -1.37
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 285.6M | 374.9M | 630.0M | 633.2M | 681.0M |
| Avg | 266.8M | 342.2M | 465.7M | 510.2M | 559.1M |
| Low | 245.3M | 298.9M | 347.9M | 382.2M | 421.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 11.0% | 40.5% | 84.1% | 36.0% | 33.5% |
| Avg | 3.7% | 28.3% | 36.1% | 9.6% | 9.6% |
| Low | -4.6% | 12.0% | 1.7% | -17.9% | -17.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.82 | -0.06 | 1.59 | 1.52 | 1.54 |
| Avg | -1.37 | -0.18 | 0.58 | 0.99 | 0.97 |
| Low | -2.33 | -0.29 | 0.09 | 0.30 | 0.55 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 164.3% | 56.0% |
| Avg | - | - | - | 71.8% | -2.4% |
| Low | - | - | - | -47.3% | -44.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.